Anti-infective Agents : Miscellaneous antibacterials
ICUBI5 “Cubicin injection” 500 mg/vial
適應症：治療下列感受性革蘭氏陽性菌引起的複雜性皮膚和皮膚組織感染(CSSSI) Staphylococcus aureus (包括 methicllin-resistant isolates)、Streptococcus pyogenes、Stretococcus agalactiae、Streptococcus dysgalactiae subsp. equisimilis 與 Entercoccus faecalis (vancomycin-susceptible strains only) Staphylococcus aureus 引起之血液感染(菌血症)包括由具有methicillin感受性及抗藥性菌株造成之右側感染性心內膜炎。
Usual dose:
Complicated skin, subcutaneous tissue infection: IV
Adult (≧18 yrs): 4 mg/kg once q24h for 7-14 days.
Staphylococcus aureus bacteremia, including right-sided endocarditis: IV
Adult (≧18 yrs): 6 mg/kg q24h for a min. of 2-6 wks.
Precaution:
Concomitant use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
Diarrhea following the administration of daptomycin.
Adverse effect:
Common: injection site reaction, pruritus, rash, constipation, diarrhea, indigestion, nausea, vomiting, increased creatine kinase level, increased creatine kinase level, dizziness, headache, insomnia, pain in limb, dyspnea.
Serious: jaundice, liver function tests abnormal, immune hypersensitivity reaction, rhabdomyolysis, renal failure.
健保使用規範：(98/1/1)
1.證實為MRSA (methicillin-resistant staphylococcus aureus) 複雜皮膚和皮膚組織感染，且證明為vancomycin抗藥菌株或使用vancomycin、teicoplanin治療失敗者，或對vancomycin、teicoplanin治療無法耐受者。
2.其他抗藥性革蘭氏陽性菌引起的複雜皮膚和皮膚組織感染，或MRSA菌血症（含右側感染性心內膜炎）；因病情需要經感染症專科醫師會診確認需要使用者（申報費用時需檢附會診及相關之病歷資料）。